Isotretinoin (oral)
A systemic retinoid prescribed for severe acne. iPLEDGE-monitored due to severe teratogenicity.
Shrinks sebaceous glands, normalises keratinisation, reduces C. acnes, addresses every pillar of acne pathophysiology.
- Research suggests may help with severe acne
- Long-term remission possible
- May help reduce the appearance of sebum
What the evidence supports.
- All skin types
- Pregnant
- Breastfeeding
- Hepatic impairment
- Hyperlipidemia
Apply early in routine, toner/essence step.
Concentration range in well-formulated products: Oral 0.5–1 mg/kg/d
Year-round; SPF non-negotiable.
Take with fatty meal for absorption (Absorica formulation excepted).
No specific deficiency signals tracked for this ingredient.
iPLEDGE pregnancy registry mandatory. Cumulative dose target 120–150 mg/kg.
Isotretinoin (oral) is a regulated medication. Use only under the guidance of a licensed physician or dermatologist. The information here is educational, Skinlumis does not dispense prescriptions or provide medical advice.
The research behind Isotretinoin (oral).
Every claim on this page traces to published research. Findings below are drawn from randomized trials and systematic reviews, each links to the study on PubMed.
American Journal of Clinical Dermatology, 2020
Journal of Cutaneous Medicine and Surgery, 2020
Journal of Advanced Research, 2015
Dermato-Endocrinology, 2011
Sign up to see how Isotretinoin (oral) fits your skin archetype and personalised protocol.